Pioglitazone Increases Gallbladder Volume in Insulin-Resistant Obese Mice

Hayder H. Al-Azzawi, Abhishek Mathur, Debao Lu, Deborah A. Swartz-Basile, Attila Nakeeb, Henry A. Pitt

Research output: Contribution to journalArticle

Abstract

Background: Both obesity and diabetes are associated with an increased incidence of gallstones. Recent animal and human data from our laboratory suggest that insulin resistance is associated with increased gallbladder volume and/or impaired gallbladder emptying. Pioglitazone is a thiazolidinedione that has been shown to improve insulin resistance. Therefore, we tested the hypothesis that pioglitazone would improve insulin resistance, decrease resting gallbladder volume and improve gallbladder response to neurotransmitters in insulin-resistant obese mice fed a 25% carbohydrate diet. Materials and methods: Twenty eight-week-old insulin-resistant obese (Lepob) mice fed a 25% carbohydrate diet for 4 weeks. Half of the animals had 0.3 g/kg pioglitazone added to their diet. At 12 weeks all animals were fasted and underwent cholecystectomy. Gallbladder volume and weight were measured, and fresh gallbladders were placed in a muscle bath to assess response to acetylcholine (ACh 10-5M), neuropeptide Y (NPY 10-8,-7,-6M) and cholecystokinin (CCK 10-10,-9,-8,-7M). Serum glucose and insulin were measured, and HOMA Index, a measure of insulin resistance, was calculated. Results: Fasting serum insulin and HOMA Index were significantly decreased (P <0.03), but gallbladder volume was significantly increased (P <0.03) in the pioglitazone treated group. Pioglitazone did not alter gallbladder weight or response to ACh, NPY, or CCK. Conclusion: These data suggest that in insulin-resistant obese mice pioglitazone 1) lowers insulin-resistance, 2) increases resting gallbladder volume, and 3) does not alter gallbladder response to neurotransmitters. Therefore, we conclude that pioglitazone, while improving insulin resistance, paradoxically increases gallbladder volume and, thereby, may increase the propensity for gallstone formation by enhancing gallbladder stasis.

Original languageEnglish (US)
Pages (from-to)192-197
Number of pages6
JournalJournal of Surgical Research
Volume136
Issue number2
DOIs
StatePublished - Dec 2006
Externally publishedYes

Fingerprint

pioglitazone
Obese Mice
Gallbladder
Insulin
Insulin Resistance
Gallstones
Diet
Neurotransmitter Agents
Gallbladder Emptying
Carbohydrates
Weights and Measures

Keywords

  • diabetes
  • gallbladder
  • insulin
  • insulin resistance
  • pioglitazone

ASJC Scopus subject areas

  • Surgery

Cite this

Al-Azzawi, H. H., Mathur, A., Lu, D., Swartz-Basile, D. A., Nakeeb, A., & Pitt, H. A. (2006). Pioglitazone Increases Gallbladder Volume in Insulin-Resistant Obese Mice. Journal of Surgical Research, 136(2), 192-197. https://doi.org/10.1016/j.jss.2006.06.022

Pioglitazone Increases Gallbladder Volume in Insulin-Resistant Obese Mice. / Al-Azzawi, Hayder H.; Mathur, Abhishek; Lu, Debao; Swartz-Basile, Deborah A.; Nakeeb, Attila; Pitt, Henry A.

In: Journal of Surgical Research, Vol. 136, No. 2, 12.2006, p. 192-197.

Research output: Contribution to journalArticle

Al-Azzawi, HH, Mathur, A, Lu, D, Swartz-Basile, DA, Nakeeb, A & Pitt, HA 2006, 'Pioglitazone Increases Gallbladder Volume in Insulin-Resistant Obese Mice', Journal of Surgical Research, vol. 136, no. 2, pp. 192-197. https://doi.org/10.1016/j.jss.2006.06.022
Al-Azzawi HH, Mathur A, Lu D, Swartz-Basile DA, Nakeeb A, Pitt HA. Pioglitazone Increases Gallbladder Volume in Insulin-Resistant Obese Mice. Journal of Surgical Research. 2006 Dec;136(2):192-197. https://doi.org/10.1016/j.jss.2006.06.022
Al-Azzawi, Hayder H. ; Mathur, Abhishek ; Lu, Debao ; Swartz-Basile, Deborah A. ; Nakeeb, Attila ; Pitt, Henry A. / Pioglitazone Increases Gallbladder Volume in Insulin-Resistant Obese Mice. In: Journal of Surgical Research. 2006 ; Vol. 136, No. 2. pp. 192-197.
@article{6d51c2ab8c364e33b1fb3543b05798e9,
title = "Pioglitazone Increases Gallbladder Volume in Insulin-Resistant Obese Mice",
abstract = "Background: Both obesity and diabetes are associated with an increased incidence of gallstones. Recent animal and human data from our laboratory suggest that insulin resistance is associated with increased gallbladder volume and/or impaired gallbladder emptying. Pioglitazone is a thiazolidinedione that has been shown to improve insulin resistance. Therefore, we tested the hypothesis that pioglitazone would improve insulin resistance, decrease resting gallbladder volume and improve gallbladder response to neurotransmitters in insulin-resistant obese mice fed a 25{\%} carbohydrate diet. Materials and methods: Twenty eight-week-old insulin-resistant obese (Lepob) mice fed a 25{\%} carbohydrate diet for 4 weeks. Half of the animals had 0.3 g/kg pioglitazone added to their diet. At 12 weeks all animals were fasted and underwent cholecystectomy. Gallbladder volume and weight were measured, and fresh gallbladders were placed in a muscle bath to assess response to acetylcholine (ACh 10-5M), neuropeptide Y (NPY 10-8,-7,-6M) and cholecystokinin (CCK 10-10,-9,-8,-7M). Serum glucose and insulin were measured, and HOMA Index, a measure of insulin resistance, was calculated. Results: Fasting serum insulin and HOMA Index were significantly decreased (P <0.03), but gallbladder volume was significantly increased (P <0.03) in the pioglitazone treated group. Pioglitazone did not alter gallbladder weight or response to ACh, NPY, or CCK. Conclusion: These data suggest that in insulin-resistant obese mice pioglitazone 1) lowers insulin-resistance, 2) increases resting gallbladder volume, and 3) does not alter gallbladder response to neurotransmitters. Therefore, we conclude that pioglitazone, while improving insulin resistance, paradoxically increases gallbladder volume and, thereby, may increase the propensity for gallstone formation by enhancing gallbladder stasis.",
keywords = "diabetes, gallbladder, insulin, insulin resistance, pioglitazone",
author = "Al-Azzawi, {Hayder H.} and Abhishek Mathur and Debao Lu and Swartz-Basile, {Deborah A.} and Attila Nakeeb and Pitt, {Henry A.}",
year = "2006",
month = "12",
doi = "10.1016/j.jss.2006.06.022",
language = "English (US)",
volume = "136",
pages = "192--197",
journal = "Journal of Surgical Research",
issn = "0022-4804",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Pioglitazone Increases Gallbladder Volume in Insulin-Resistant Obese Mice

AU - Al-Azzawi, Hayder H.

AU - Mathur, Abhishek

AU - Lu, Debao

AU - Swartz-Basile, Deborah A.

AU - Nakeeb, Attila

AU - Pitt, Henry A.

PY - 2006/12

Y1 - 2006/12

N2 - Background: Both obesity and diabetes are associated with an increased incidence of gallstones. Recent animal and human data from our laboratory suggest that insulin resistance is associated with increased gallbladder volume and/or impaired gallbladder emptying. Pioglitazone is a thiazolidinedione that has been shown to improve insulin resistance. Therefore, we tested the hypothesis that pioglitazone would improve insulin resistance, decrease resting gallbladder volume and improve gallbladder response to neurotransmitters in insulin-resistant obese mice fed a 25% carbohydrate diet. Materials and methods: Twenty eight-week-old insulin-resistant obese (Lepob) mice fed a 25% carbohydrate diet for 4 weeks. Half of the animals had 0.3 g/kg pioglitazone added to their diet. At 12 weeks all animals were fasted and underwent cholecystectomy. Gallbladder volume and weight were measured, and fresh gallbladders were placed in a muscle bath to assess response to acetylcholine (ACh 10-5M), neuropeptide Y (NPY 10-8,-7,-6M) and cholecystokinin (CCK 10-10,-9,-8,-7M). Serum glucose and insulin were measured, and HOMA Index, a measure of insulin resistance, was calculated. Results: Fasting serum insulin and HOMA Index were significantly decreased (P <0.03), but gallbladder volume was significantly increased (P <0.03) in the pioglitazone treated group. Pioglitazone did not alter gallbladder weight or response to ACh, NPY, or CCK. Conclusion: These data suggest that in insulin-resistant obese mice pioglitazone 1) lowers insulin-resistance, 2) increases resting gallbladder volume, and 3) does not alter gallbladder response to neurotransmitters. Therefore, we conclude that pioglitazone, while improving insulin resistance, paradoxically increases gallbladder volume and, thereby, may increase the propensity for gallstone formation by enhancing gallbladder stasis.

AB - Background: Both obesity and diabetes are associated with an increased incidence of gallstones. Recent animal and human data from our laboratory suggest that insulin resistance is associated with increased gallbladder volume and/or impaired gallbladder emptying. Pioglitazone is a thiazolidinedione that has been shown to improve insulin resistance. Therefore, we tested the hypothesis that pioglitazone would improve insulin resistance, decrease resting gallbladder volume and improve gallbladder response to neurotransmitters in insulin-resistant obese mice fed a 25% carbohydrate diet. Materials and methods: Twenty eight-week-old insulin-resistant obese (Lepob) mice fed a 25% carbohydrate diet for 4 weeks. Half of the animals had 0.3 g/kg pioglitazone added to their diet. At 12 weeks all animals were fasted and underwent cholecystectomy. Gallbladder volume and weight were measured, and fresh gallbladders were placed in a muscle bath to assess response to acetylcholine (ACh 10-5M), neuropeptide Y (NPY 10-8,-7,-6M) and cholecystokinin (CCK 10-10,-9,-8,-7M). Serum glucose and insulin were measured, and HOMA Index, a measure of insulin resistance, was calculated. Results: Fasting serum insulin and HOMA Index were significantly decreased (P <0.03), but gallbladder volume was significantly increased (P <0.03) in the pioglitazone treated group. Pioglitazone did not alter gallbladder weight or response to ACh, NPY, or CCK. Conclusion: These data suggest that in insulin-resistant obese mice pioglitazone 1) lowers insulin-resistance, 2) increases resting gallbladder volume, and 3) does not alter gallbladder response to neurotransmitters. Therefore, we conclude that pioglitazone, while improving insulin resistance, paradoxically increases gallbladder volume and, thereby, may increase the propensity for gallstone formation by enhancing gallbladder stasis.

KW - diabetes

KW - gallbladder

KW - insulin

KW - insulin resistance

KW - pioglitazone

UR - http://www.scopus.com/inward/record.url?scp=33750956901&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750956901&partnerID=8YFLogxK

U2 - 10.1016/j.jss.2006.06.022

DO - 10.1016/j.jss.2006.06.022

M3 - Article

C2 - 17045610

AN - SCOPUS:33750956901

VL - 136

SP - 192

EP - 197

JO - Journal of Surgical Research

JF - Journal of Surgical Research

SN - 0022-4804

IS - 2

ER -